Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62.9M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
-1.3M
-
Total reported value, excl. options
-
$29.6M
-
Value change
-
-$2.65M
-
Put/Call ratio
-
1.58
-
Number of buys
-
32
-
Number of sells
-
-46
-
Price
-
$0.98
Significant Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q1 2025
112 filings reported holding PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 62.9M outstanding shares and own 48.07% of the company stock.
Largest 10 shareholders include Pfizer Inc (7.03M shares), Laurion Capital Management LP (3.63M shares), BlackRock, Inc. (3.27M shares), MILLENNIUM MANAGEMENT LLC (2.49M shares), VANGUARD GROUP INC (2.44M shares), GEODE CAPITAL MANAGEMENT, LLC (1.11M shares), TANG CAPITAL MANAGEMENT LLC (1.1M shares), Palo Alto Investors LP (1.04M shares), STATE STREET CORP (932K shares), and Aberdeen Group plc (913K shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.